Autologous mesenchymal stem cell therapy (Bioinova/Charles University)

N/A

Report date: 2023/01/12 15:31:40

Base Information

Drug NameAutologous mesenchymal stem cell therapy (Bioinova/Charles University)

Drug Alias NameAMSCAMSC-RC-001AMSC-DSD001

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy

Mechanisms of ActionCell replacements

TargetsNot applicable

Therapy Area/IndicationsRotator Cuff InjuriesAmyotrophic Lateral Sclerosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesBioinova

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBioinova Sro

Active IndicationsN/A

Inactive IndicationsRotator Cuff InjuriesAmyotrophic Lateral Sclerosis

Other Information

ATC CodeN/A